Search
-
Risk
In an age of compounding and interconnected crises, the only certainty is more uncertainty. Here’s what brands and policymakers need to know about the risk of business and business of risk.
-
How companies should plan around a pivotal global election year
As voters around the world cast their ballots, brands and businesses should stay prepared for a range of economic, social, and regulatory scenarios. Ipsos’ Nick Chiarelli explains how.
-
Michael Link appointed as President of Ipsos U.S. Public Affairs
Link, a distinguished researcher and leader, will lead Ipsos’ Public Affairs practice in the U.S.
-
An economic meltdown is the doomsday Americans fear the most. Here’s why
One in five list climate change as the catastrophe they are most worried about, according to new polling from the Ipsos Consumer Tracker. One in four pick World War III. Fully a third say a total economic collapse in the U.S. is what keeps them up at night.
-
Where Americans stand on generative AI
Below are five charts on the state of generative AI models and how the public feels when it comes to AI regulation
-
Ipsos Global Consumer Confidence Index Election Tracker: March 2024
A monthly overview of consumer sentiment in countries holding elections in 2024
-
One in four current undergraduate students are at risk of not completing college
Finances, changes in motivation, and mental health are the top reasons at risk students have considered leaving school according to Sallie Mae/Ipsos polling
-
Three in five small businesses are concerned about cybersecurity threats
The quarterly Ipsos/MetLife/U.S. Chamber of Commerce Small Business Index in Q1 2024 is stable from Q4 2023
-
What presidential approval and the main issue say about Biden’s chances at reelection
Below are five charts on where Biden stands among the American public and what these key indicators say about Biden as we inch closer and closer to the 2024 election
-
Most Americans support access to medication abortion
Axios/Ipsos poll: Four in five Americans say the FDA should continue approving and regulating medicines in the U.S.